{"id":73083,"date":"2024-11-12T07:32:10","date_gmt":"2024-11-12T06:32:10","guid":{"rendered":"https:\/\/xenodochial-khorana.51-75-243-206.plesk.page\/transaction\/equity-fundraising-for-a-biotech\/"},"modified":"2024-11-12T07:32:10","modified_gmt":"2024-11-12T06:32:10","slug":"equity-fundraising-for-a-biotech","status":"publish","type":"transaction","link":"https:\/\/fournel-advisory.com\/en\/transaction\/equity-fundraising-for-a-biotech\/","title":{"rendered":"EQUITY FUNDRAISING FOR A BIOTECH"},"content":{"rendered":"<p><b>FOURNEL ADVISORY SUPPORTS A FRENCH BIOTECH COMPANY IN ITS FUNDRAISING TO MARKET AND COMMERCIALISE ITS TECHNOLOGY.<\/b><\/p>\n\n<p>Founded in 2016 by Jean-Fran\u00e7ois CHATAL, a pioneer in nuclear medicine, NAOGEN PHARMA develops, produces and markets innovative radiopharmaceutical products for non-invasive molecular imaging (PET \u2013 Positron Emission Tomography) for hospital nuclear medicine departments.<\/p>\n\n<p>FOURNEL ADVISORY assisted NAOGEN PHARMA in raising funds from private and institutional investors in order to obtain marketing authorization for its products by 2022.<\/p>","protected":false},"excerpt":{"rendered":"<p>FOURNEL ADVISORY SUPPORTS A FRENCH BIOTECH COMPANY IN ITS FUNDRAISING TO MARKET AND COMMERCIALISE ITS TECHNOLOGY. Founded in 2016 by Jean-Fran\u00e7ois CHATAL, a pioneer in nuclear medicine, NAOGEN PHARMA develops, produces and markets innovative radiopharmaceutical products for non-invasive molecular imaging (PET \u2013 Positron Emission Tomography) for hospital nuclear medicine departments. FOURNEL ADVISORY assisted NAOGEN PHARMA [&hellip;]<\/p>","protected":false},"author":1,"featured_media":73036,"template":"","type_transaction":[100],"class_list":["post-73083","transaction","type-transaction","status-publish","has-post-thumbnail","hentry","type_transaction-leveraged-operation"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>EQUITY FUNDRAISING FOR A BIOTECH - FOURNEL ADVISORY<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fournel-advisory.com\/en\/transaction\/equity-fundraising-for-a-biotech\/?lang=en\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EQUITY FUNDRAISING FOR A BIOTECH - FOURNEL ADVISORY\" \/>\n<meta property=\"og:description\" content=\"FOURNEL ADVISORY SUPPORTS A FRENCH BIOTECH COMPANY IN ITS FUNDRAISING TO MARKET AND COMMERCIALISE ITS TECHNOLOGY. Founded in 2016 by Jean-Fran\u00e7ois CHATAL, a pioneer in nuclear medicine, NAOGEN PHARMA develops, produces and markets innovative radiopharmaceutical products for non-invasive molecular imaging (PET \u2013 Positron Emission Tomography) for hospital nuclear medicine departments. FOURNEL ADVISORY assisted NAOGEN PHARMA [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fournel-advisory.com\/en\/transaction\/equity-fundraising-for-a-biotech\/?lang=en\" \/>\n<meta property=\"og:site_name\" content=\"FOURNEL ADVISORY\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fournel-advisory.com\/wp-content\/uploads\/2024\/11\/Capture-decran-2022-01-02-a-15.12.01-1024x1024-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en\",\"url\":\"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en\",\"name\":\"EQUITY FUNDRAISING FOR A BIOTECH - FOURNEL ADVISORY\",\"isPartOf\":{\"@id\":\"https:\/\/fournel-advisory.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en#primaryimage\"},\"image\":{\"@id\":\"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fournel-advisory.com\/wp-content\/uploads\/2024\/11\/Thumbstone-NAOGEN-ENG-1024x1024-1.png\",\"datePublished\":\"2024-11-12T06:32:10+00:00\",\"dateModified\":\"2024-11-12T06:32:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en#primaryimage\",\"url\":\"https:\/\/fournel-advisory.com\/wp-content\/uploads\/2024\/11\/Thumbstone-NAOGEN-ENG-1024x1024-1.png\",\"contentUrl\":\"https:\/\/fournel-advisory.com\/wp-content\/uploads\/2024\/11\/Thumbstone-NAOGEN-ENG-1024x1024-1.png\",\"width\":1024,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/fournel-advisory.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transactions\",\"item\":\"https:\/\/fournel-advisory.com\/transactions\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"EQUITY FUNDRAISING FOR A BIOTECH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fournel-advisory.com\/#website\",\"url\":\"https:\/\/fournel-advisory.com\/\",\"name\":\"FOURNEL ADVISORY\",\"description\":\"Une soci\u00e9t\u00e9 de conseil sp\u00e9cialis\u00e9e en fusions-acquisitions, lev\u00e9e de fonds et situations sp\u00e9ciales.\",\"publisher\":{\"@id\":\"https:\/\/fournel-advisory.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fournel-advisory.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fournel-advisory.com\/#organization\",\"name\":\"FOURNEL ADVISORY\",\"url\":\"https:\/\/fournel-advisory.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/fournel-advisory.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fournel-advisory.com\/wp-content\/uploads\/2024\/08\/Logo-FA-Blanc.png\",\"contentUrl\":\"https:\/\/fournel-advisory.com\/wp-content\/uploads\/2024\/08\/Logo-FA-Blanc.png\",\"width\":2363,\"height\":1323,\"caption\":\"FOURNEL ADVISORY\"},\"image\":{\"@id\":\"https:\/\/fournel-advisory.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EQUITY FUNDRAISING FOR A BIOTECH - FOURNEL ADVISORY","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fournel-advisory.com\/en\/transaction\/equity-fundraising-for-a-biotech\/?lang=en","og_locale":"en_GB","og_type":"article","og_title":"EQUITY FUNDRAISING FOR A BIOTECH - FOURNEL ADVISORY","og_description":"FOURNEL ADVISORY SUPPORTS A FRENCH BIOTECH COMPANY IN ITS FUNDRAISING TO MARKET AND COMMERCIALISE ITS TECHNOLOGY. Founded in 2016 by Jean-Fran\u00e7ois CHATAL, a pioneer in nuclear medicine, NAOGEN PHARMA develops, produces and markets innovative radiopharmaceutical products for non-invasive molecular imaging (PET \u2013 Positron Emission Tomography) for hospital nuclear medicine departments. FOURNEL ADVISORY assisted NAOGEN PHARMA [&hellip;]","og_url":"https:\/\/fournel-advisory.com\/en\/transaction\/equity-fundraising-for-a-biotech\/?lang=en","og_site_name":"FOURNEL ADVISORY","og_image":[{"width":1024,"height":1024,"url":"https:\/\/fournel-advisory.com\/wp-content\/uploads\/2024\/11\/Capture-decran-2022-01-02-a-15.12.01-1024x1024-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en","url":"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en","name":"EQUITY FUNDRAISING FOR A BIOTECH - FOURNEL ADVISORY","isPartOf":{"@id":"https:\/\/fournel-advisory.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en#primaryimage"},"image":{"@id":"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en#primaryimage"},"thumbnailUrl":"https:\/\/fournel-advisory.com\/wp-content\/uploads\/2024\/11\/Thumbstone-NAOGEN-ENG-1024x1024-1.png","datePublished":"2024-11-12T06:32:10+00:00","dateModified":"2024-11-12T06:32:10+00:00","breadcrumb":{"@id":"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en#primaryimage","url":"https:\/\/fournel-advisory.com\/wp-content\/uploads\/2024\/11\/Thumbstone-NAOGEN-ENG-1024x1024-1.png","contentUrl":"https:\/\/fournel-advisory.com\/wp-content\/uploads\/2024\/11\/Thumbstone-NAOGEN-ENG-1024x1024-1.png","width":1024,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/fournel-advisory.com\/transaction\/equity-fundraising-for-a-biotech\/?lang=en#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/fournel-advisory.com\/"},{"@type":"ListItem","position":2,"name":"Transactions","item":"https:\/\/fournel-advisory.com\/transactions\/"},{"@type":"ListItem","position":3,"name":"EQUITY FUNDRAISING FOR A BIOTECH"}]},{"@type":"WebSite","@id":"https:\/\/fournel-advisory.com\/#website","url":"https:\/\/fournel-advisory.com\/","name":"FOURNEL ADVISORY","description":"Une soci\u00e9t\u00e9 de conseil sp\u00e9cialis\u00e9e en fusions-acquisitions, lev\u00e9e de fonds et situations sp\u00e9ciales.","publisher":{"@id":"https:\/\/fournel-advisory.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fournel-advisory.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/fournel-advisory.com\/#organization","name":"FOURNEL ADVISORY","url":"https:\/\/fournel-advisory.com\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/fournel-advisory.com\/#\/schema\/logo\/image\/","url":"https:\/\/fournel-advisory.com\/wp-content\/uploads\/2024\/08\/Logo-FA-Blanc.png","contentUrl":"https:\/\/fournel-advisory.com\/wp-content\/uploads\/2024\/08\/Logo-FA-Blanc.png","width":2363,"height":1323,"caption":"FOURNEL ADVISORY"},"image":{"@id":"https:\/\/fournel-advisory.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/fournel-advisory.com\/en\/wp-json\/wp\/v2\/transaction\/73083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fournel-advisory.com\/en\/wp-json\/wp\/v2\/transaction"}],"about":[{"href":"https:\/\/fournel-advisory.com\/en\/wp-json\/wp\/v2\/types\/transaction"}],"author":[{"embeddable":true,"href":"https:\/\/fournel-advisory.com\/en\/wp-json\/wp\/v2\/users\/1"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fournel-advisory.com\/en\/wp-json\/wp\/v2\/media\/73036"}],"wp:attachment":[{"href":"https:\/\/fournel-advisory.com\/en\/wp-json\/wp\/v2\/media?parent=73083"}],"wp:term":[{"taxonomy":"type_transaction","embeddable":true,"href":"https:\/\/fournel-advisory.com\/en\/wp-json\/wp\/v2\/type_transaction?post=73083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}